Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
FYI the $2.5 million deal was signed prior to merger talks.
Like my calculations before IMO the combined companies will have over $8 million in revenue and be profitable.
One times sales = .04 in today's prices. I'm also speculating they drop $1 million to net income. That's .005 EPS in today's prices (1,000,000 / 200,000,000 post RM shares but pre-split.) PE of 15 will give a share price of .075
Now MP I know they can't exceed the 75 million but I'm trying to show what's going on for a buy now.
I still see a buy up to .04 as safe with a chance to go above .10
AND I'm sure shares after the deal will be restricted.
I want them .005's :)
Sure would love to get my hands on some of them .005's :)
UNVC .0001/.0002 Should I take a chance here? Or throw it out with the rest of the garbage?
.015 and dropping fast.
What a shame....can't say I blame him.
I may start to rebuy a position here....hesitantly.
I had VERY high hopes for this one until the financing.
I haven't been able to find out.
But experience says it's toxic....and as you can see the price has lost 75% of its value since the financing started.
Sure does move down easily.
Come to pappa :)
Healthcare
Understanding the complex business challenges facing healthcare services institutions, the Irus Group has developed the next generation of business intelligence tools and services for the health care delivery system such as Hospitals (Provider), Insurance Companies (Payer), Provider (Physicians) and ultimately the consumers (Patients). Clearly the delivery of quality care to patients is the core business of any healthcare provider organization, but non-integrated legacy systems and staffing shortages have resulted in deviations from critical standards in the delivery of care to patients. Unintended consequences of these deviations to healthcare procedures may include:
* Unfavorable clinical outcomes
* Increased cost of care
* Higher malpractice costs
* Inappropriate use of resources
* Loss of reputation
* Loss of accreditation
Quality Improvement
Irus Group is uniquely suited to members of the Healthcare Delivery providers to effectively manage quality of care and drive sustainable improvements by measuring and viewing clinical performance, resource utilization, cost-effectiveness, pathway development and evidence-based decision making. Creating a true evidence-based culture requires healthcare providers to empower management and staff with analytic and knowledge management capabilities for strategic decision making that will lead to:
* Increased patient safety
* Improved quality of care
* More effective risk management practices
* Better application of best practices for care protocols
Provider Analysis and Classification
The Irus Group Healthcare data management, analytic and reporting solutions enable clients to uncover that critical information - and empower physicians to make evidence-based changes to practice patterns by:
* Consolidating data for measuring and reporting practice and prescribing patterns
* Tracking by specific disease, population, DRG, etc
* Surfacing physician measures to monitor cost, use and quality at a high level, while also allowing drill-down to more detailed data.
Complex Data Analysis & Reporting
The Irus Group Healthcare Practice gives you the ability to assemble highly sophisticated predictive models that can analyze and predict such utilization variables as:
* Demand for future services by geography, medical need and payer type
* When future need will occur (including time of day and, more importantly, the point in time during the patient's health history)
* How future encounters will take place (emergency, routine visit, hospital admission, etc.)
* Financial encounter projections, including how much revenue future encounters will produce, payer type, what it will cost, etc.
By forecasting better, Healthcare organizations can improve planning capabilities across the board. You can size service offerings and determine where to locate them, keeping both patient satisfaction and revenue high. This information can be used to support:
* Revenue prediction
* Cost prediction
* Investment decision support
* Knowledge and skills management
Does IFRX still have INFERhealth as part of their offerings?
If so, what does it do? (I'm thinking FVRL like)
If I were a creditor of IFRX I'd be salivating getting paid in shares around .02 with Irus revenues and being profitable.
They'll be able to sell them over .04 IMO - DOUBLING their money
Those numbers sure look familiar :)
The $1 million in financing.
Never mind
Great quextion chesty. It looks like it may be time to load.
Call me skeptical but I think you'll be able to get some under .50
Not when you're riding free shares and a RM to add value is coming. LMFAO.
If you says so. lol
IFRX gonna fly.....volume pouring in :)
UNVC .0001 lol POS
Somebody get the lights
If you all put the buying and effort pumping IFRX at .015 like these other stocks you'd have a 10-bagger lol
What is good about this news?
We have entered into a merger agreement with The Irus Group that has generated some additional revenue and we expect to pursue additional business opportunities together prior to the effective time of the merger. We expect to reduce some of our overhead costs by combining offices and personnel functions to reduce the expected increase in staff for anticipated sales. We will need to generate significant additional revenue to support our projected increases in staffing and other operating expenses, which we cannot give any assurance we will be able to accomplish. Our current operating expenditures are approximately $125,000 per month to support our operations, and under our projected growth plan, we expect to double that amount to approximately $250,000 per month by the end of fiscal 2009. Along with revenues from our existing contracts, we believe that we will need to raise capital to address the reduction in debt required for the merger to become effective and to allow us to stay in business. We estimate that we will require approximately $1,000,000 in additional capital to sustain our operations at their current level through fiscal 2009 and that we will require as much as $3,000,000 in additional revenues or $1,500,000 in additional funding to achieve our projected growth plan.
To clarify I'm using pre split numbers to show that IMO it's worth .04 NOW at worst.
Dude....whether RS is before or after merger it's all the same numbers....10/1 RS using my numbers gives them 20 million OS.
They go up to 60 million prior to RS to pay off debt and RS 10 to 1 to 6 million........then issue Irus 14 million to get them to 20 million OS
In that case multiply my projected pps of .04-.10 to .40-1.00
It all works
I still think my OS calculations are correct and a buy up to .04 is relatively safe...even with the RS coming....
$8 million annual revenue divided by 200 million shares is .04 per share in revenue.
Drop $1.5-2.0 million to bottom line and EPS of .0075-.01....10 PE and pps of .075-.10
Buy and hold :)
Sorry GC but I wacked the bid at .052 :)
How much?
Hell....let's make it $5
Any of the 3 Stooges still alive?
expects??
Hope so.....after seeing some of these pinkies play with words I'd rather see it worded more definitively
LYFETEC, Inc., formerly Tri-Star Holdings, Inc. (PINKSHEETS: TSHL) has officially received approval of its FDA registration. The company filed the registration in order to become an FDA approved medical distribution company. This registration enables the company to sell and distribute approved medical products throughout the U.S., effective immediately.
Some funny wording
IN ORDER TO BECOME????
Did the FDA approve? Or did somebody from company "approve" sending in the registration?
TSHL Level 2 looks good.....NITE all the way out to .001
Let's see if it can brreak .0003 this time
LOL
Market GREEN.......CEMJQ RED
Go get em crynik
Irus "buying" $2.5 million of IFRX product over next 2 years.
That's $1.25 million per year....my guess is that'll generate revenue of $2 million per year.
So Irus original $6 million per year plus new business from IFRX of $2 million per year will give them $8 million per year in revenues.
Using similar model from my last calculations I see a price of .04-.15 as possible :)
sure would have been nice to see this PR'd
CYIO I do actually.
But agree that there IR is a joke. With their history we may need a quarter showing revenue over $1.2 million and EPS of .02+